Pharminent

FDA panel backs Novartis’ CAR-T therapy CTL019

Novartis’ CTL019 has taken a giant leap towards the finishing line in the race to get the first cancer killing CAR-T cell therapy on the market having won the support of an FDA advisory panel. http://www.pharmatimes.com/news/fda_panel_backs_novartis_car-t_therapy_ctl019_1198432

Filed under: Cancer, Immunotherapy